Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall Survival Celsion to Conduct a Thorough Analysis of the Unblinded Study Data Before Making a Final Determination Conference Call

LAWRENCEVILLE, N.J , June 25, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, today affirmed that the independent Data Monitoring Committee (iDMC) is scheduled to meet during the first half of July to conduct the second pre-planned interim safety

Lawrenceville, NJ , June 24, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced public offering of 2,666,667 shares of common stock, resulting in net proceeds of $9.3 million , after deducting

Lawrenceville, NJ , June 22, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of its common stock at an offering price of $3.75 per share, less

  Excellent Surgical Response Noted at the Higher, 100 mg/m 2 Dose  Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month Period, Up to 17 Doses LAWRENCEVILLE, N.J. , May 29, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:

Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J , May 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug development company, today announced financial results for the three

LAWRENCEVILLE, N.J. , May 08, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the first quarter ended March 31, 2020 and provide an update on its development programs for ThermoDox ® , its

Added Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events Sale of an Additional $2.0 Million of NOL’s Expected in the 4 th Quarter of 2020 LAWRENCEVILLE, N.J. , April 23, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology

Independent Data Monitoring Committee is Expected to Meet in July 2020  to Evaluate Overall Survival Data LAWRENCEVILLE, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , an oncology drug-development company, announces that the prescribed minimum number of events of 158

Hazard Ratio of 0.53 for PFS in the Phase I Intent-To-Treat Population Synthetic Randomization Provides Means to Evaluate Strategies to Accelerate GEN-1 Clinical Program for Newly Diagnosed Stage III/IV Ovarian Cancer LAWRENCEVILLE, N.J. , March 26, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation